Pictet Asset Management Holding SA Grows Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Pictet Asset Management Holding SA increased its holdings in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 9.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 756,297 shares of the company's stock after buying an additional 68,317 shares during the quarter. Pictet Asset Management Holding SA owned 1.69% of Y-mAbs Therapeutics worth $5,922,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. State Street Corp grew its stake in shares of Y-mAbs Therapeutics by 50.4% during the third quarter. State Street Corp now owns 1,209,781 shares of the company's stock worth $15,909,000 after acquiring an additional 405,169 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Y-mAbs Therapeutics by 221.9% in the 4th quarter. JPMorgan Chase & Co. now owns 97,660 shares of the company's stock worth $765,000 after purchasing an additional 67,325 shares in the last quarter. Barclays PLC grew its position in Y-mAbs Therapeutics by 433.4% during the 3rd quarter. Barclays PLC now owns 69,222 shares of the company's stock worth $910,000 after purchasing an additional 56,244 shares during the last quarter. Geode Capital Management LLC increased its stake in Y-mAbs Therapeutics by 6.2% during the 3rd quarter. Geode Capital Management LLC now owns 813,489 shares of the company's stock valued at $10,699,000 after purchasing an additional 47,846 shares in the last quarter. Finally, AlphaQuest LLC raised its holdings in shares of Y-mAbs Therapeutics by 6,911.6% in the fourth quarter. AlphaQuest LLC now owns 27,135 shares of the company's stock worth $212,000 after buying an additional 26,748 shares during the last quarter. 70.85% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling at Y-mAbs Therapeutics

In other news, insider Thomas Gad sold 10,810 shares of Y-mAbs Therapeutics stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $5.23, for a total value of $56,536.30. Following the sale, the insider now owns 202,721 shares in the company, valued at $1,060,230.83. This trade represents a 5.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 22.50% of the stock is owned by corporate insiders.

Y-mAbs Therapeutics Stock Performance

NASDAQ YMAB traded down $0.19 during mid-day trading on Tuesday, reaching $4.09. 235,473 shares of the stock were exchanged, compared to its average volume of 334,122. Y-mAbs Therapeutics, Inc. has a 1 year low of $4.03 and a 1 year high of $17.78. The business's 50 day moving average is $5.30 and its 200-day moving average is $8.98. The company has a market capitalization of $184.94 million, a P/E ratio of -7.57 and a beta of 0.71.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last posted its earnings results on Tuesday, March 4th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). The business had revenue of $26.50 million for the quarter, compared to analyst estimates of $26.70 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same quarter last year, the business earned ($0.02) earnings per share. Equities analysts predict that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on YMAB. Morgan Stanley dropped their price objective on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a report on Wednesday, March 5th. Bank of America cut their price objective on Y-mAbs Therapeutics from $14.00 to $12.00 and set a "neutral" rating on the stock in a report on Wednesday, March 5th. HC Wainwright dropped their target price on Y-mAbs Therapeutics from $22.00 to $12.00 and set a "buy" rating on the stock in a research report on Friday, March 21st. Truist Financial cut their price target on shares of Y-mAbs Therapeutics from $21.00 to $18.00 and set a "buy" rating on the stock in a report on Wednesday, March 5th. Finally, Wedbush restated an "outperform" rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $18.30.

Y-mAbs Therapeutics Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.